The IRF5 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colon adenocarcinoma epithelial cell line, providing a powerful loss-of-function model for dissecting interferon regulatory factor 5 (IRF5)-dependent signaling. This product consists of a heterogenous pool of cells harboring targeted gene disruption at the IRF5 locus, generated via CRISPR/Cas9-mediated gene disruption, without isolation of single-cell clones. The polyclonal nature enables the study of IRF5 deficiency in a genetically diverse cellular context, reducing clonal artifacts while preserving the core null phenotype. Researchers can employ this tool to interrogate innate immune signaling cascades and inflammatory responses in an intestinal epithelial background, with broad relevance to autoimmune and cancer biology.
HT29 cells are a well-characterized human colon adenocarcinoma epithelial cell line isolated from a primary colorectal tumor. They exhibit properties of enterocytic differentiation and are widely used to model intestinal barrier function, colorectal cancer pathogenesis, and mucosal immunity. The cells form polarized monolayers with tight junctions, making them particularly suitable for studying epithelial integrity, cytokine responses, and host?Cmicrobe interactions. Their malignant origin and activation of oncogenic pathways, such as mutant BRAF and PI3K signaling, provide a clinically relevant platform for colorectal cancer research. Combining IRF5 knockout with this established model offers a unique opportunity to explore how IRF5 contributes to inflammatory and oncogenic processes in the gut epithelium.
IRF5 is a transcription factor critically involved in innate immunity and inflammation. It is activated downstream of Toll-like receptor (TLR) signaling, particularly TLR7/9 ligands such as CpG DNA, and RIG-I-like receptor pathways. Upon stimulation, IRF5 is phosphorylated by TBK1 and IKK??, leading to its homodimerization, nuclear translocation, and transcriptional regulation of type I interferons (IFNA, IFNB) and pro-inflammatory cytokines (IL6, TNF, IL12B). IRF5 interacts with key adaptors and signaling mediators, including MyD88, TRAF6, IRF3, and NF-??B p65, and can form complexes with IRF4 to modulate target gene expression. It directly promotes the expression of chemokines CXCL10 and CCL5, orchestrating immune cell recruitment. Disruption of IRF5, therefore, impairs multiple arms of the innate immune response, attenuating interferon-stimulated gene expression and dampening inflammatory networks.
In the context of HT29 cells, IRF5 knockout holds particular significance for understanding colorectal cancer and inflammatory bowel disease (IBD). IRF5 expression has been linked to tumor-associated inflammation and macrophage polarization in the colorectal microenvironment. Its loss in intestinal epithelial cells may alter cytokine secretion profiles and barrier function, providing insights into how epithelial-derived IRF5 contributes to chronic inflammation and tumor progression. This model enables the dissection of epithelial-intrinsic versus immune-cell effects by studying cytokine outputs, tight junction integrity, and responses to microbial ligands. The polyclonal population avoids clonal selection biases, ensuring that observed phenotypes reflect the general consequences of IRF5 deficiency rather than artifacts of monoclonal expansion.
This IRF5 knockout cell model supports a wide range of research applications, including the investigation of innate immune signaling mechanisms, functional studies of IRF5 in colorectal cancer, and drug target validation for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sj?gren’s syndrome. It facilitates analysis of macrophage polarization and intestinal barrier function in an IRF5-deficient background. Typical assays include Western blotting and RT-qPCR for IRF5 confirmation, RNA-seq for transcriptomic profiling, ELISA for secreted cytokines (e.g., IFN-??, IL-6), flow cytometry for surface markers, interferon-stimulated response element (ISRE) reporter assays, and transepithelial electrical resistance (TEER) measurements for barrier integrity. Co-culture with immune cells and drug sensitivity studies further extend the model’s utility. For more information, please contact Ascent Research.
